In This Episode
Novavax’s vaccine has shown 89 per cent efficacy in UK trials. The government has bought 60 million doses of the jab, and it’s expected that production will begin in Teesside later this year. But, as the EU’s rollout languishes and their row with AstraZeneca escalates, should Britain consider giving away its vaccines? Katy Balls speaks to James Forsyth and Fraser Nelson.
Comments
Join the debate, free for a month
Be part of the conversation with other Spectator readers by getting your first month free.
UNLOCK ACCESS Try a month freeAlready a subscriber? Log in